James G. Ham
No más puestos en curso
Perfil
James G.
Ham worked as Vice President-Information Technology at Bristol Myers Squibb Co. from 1994 to 2001.
He then worked as Chief Financial Officer, Secretary, Treasurer & VP at NitroMed, Inc. from 2004 to 2008.
From 2008 to 2013, he served as Chief Financial Officer at Inotek Pharmaceuticals Corp.
He also worked as Vice President-Finance at Infinity Pharmaceuticals, Inc. and as Chief Financial Officer at Clearview Group.
Mr. Ham holds an MBA degree from St. John's University and an undergraduate degree from Villanova University.
Antiguos cargos conocidos de James G. Ham.
| Empresas | Cargo | Fin |
|---|---|---|
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Director Financiero/CFO | 01/01/2013 |
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Director Financiero/CFO | 11/04/2008 |
| BRISTOL-MYERS SQUIBB COMPANY | Director Técnico/Científico/I+D | 01/01/2001 |
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Clearview Group
 Clearview Group Miscellaneous Commercial ServicesCommercial Services Clearview Group provides strategic management services. The private company is based in Miller Place, NY. The company was founded by Shamez Kanji. | Director Financiero/CFO | - |
Formación de James G. Ham.
| Villanova University | Undergraduate Degree |
| St. John's University | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | Health Technology |
Clearview Group
Clearview Group Miscellaneous Commercial ServicesCommercial Services Clearview Group provides strategic management services. The private company is based in Miller Place, NY. The company was founded by Shamez Kanji. | Commercial Services |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | Health Technology |
- Bolsa de valores
- Insiders
- James G. Ham
